{"id":"W2111404068","doi":"10.1016/s1470-2045(14)70012-9","title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":978,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; F. Hoffmann-La Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Population; Oncology; Progression-free survival; Metastatic melanoma; Chemotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0286159142605539,"score_gpt":0.3339014764236995,"score_spread":0.3052855621631456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}